Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{187896,
        author = {Reeja Roy and Sherin Thomas and Divya Jyothi S and Susheela Rani S},
        title = {Levetiracetam: An Exploration of Neuropsychiatric Abnormalities},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {6},
        pages = {7128-7139},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=187896},
        abstract = {Levetiracetam is a second-generation anti-epileptic drug that has become a preferred treatment option for epilepsy due to its highly favourable pharmacological profile. It was synthesized in the 1980s and gained approval in various countries in the early 2000s. This review provides detailed insight into the mechanism, pharmacokinetic characteristics, dosing, indications and neuropsychiatric abnormalities caused by levetiracetam. A comprehensive literature search was conducted using PubMed, Elsevier, and ScienceDirect databases and the search covered publications available till date. 
Research conducted over the years has shown an increased risk of developing various neuropsychiatric abnormalities associated with levetiracetam use. These side effects may include agitation, aggression, hostility, rage, delirium, psychosis, hallucinations, somnolence, depression, restlessness, and exacerbation of seizures. Many of these effects are dose-dependent and usually resolve upon discontinuation of the drug. Additionally, some studies have explored the potential role of pyridoxine in managing these behavioural effects.
Long-term monitoring during initial treatment is vital for detecting and managing complications. Supplements like magnesium, N-acetylcysteine, melatonin, and omega-3 fatty acids may offer neuroprotective and mood-stabilizing benefits, but further clinical trials are needed to confirm their effectiveness in levetiracetam therapy. Ongoing research on strategies to minimize adverse effects will enhance treatment value and epilepsy management.},
        keywords = {Levetiracetam; anti-epileptic drug; neuropsychiatric abnormalities; psychiatric and behavioural adverse reactions},
        month = {November},
        }